Testicular cancer is rising in young men, and remains among the most curable

Testicular cancer is the most common cancer in young men, and its incidence has been climbing for decades — yet it is also among the most curable cancers there is, with deaths a small fraction of cases [s1]. Because outcomes are already so good and there is no evidence that looking for it early in men without symptoms helps, the major guideline bodies recommend against routine screening, including the self-exam many men assume they should perform [s2].

A young man's cancer, and a growing one

Most cancers are diseases of old age. Testicular cancer is the exception, concentrated in adolescents and young adults, which is part of why it looms large despite being uncommon in absolute terms [s1]. A Global Burden of Disease analysis counted 91,507 new cases worldwide in 2021, against 11,388 deaths and 560,921 disability-adjusted life years lost [s1].

The trend is unambiguously upward. Between 1990 and 2021, global cases rose by 136%, deaths by 49%, and the age-standardised incidence rate climbed from 1.45 to 2.31 per 100,000 [s1]. The increase is steepest in wealthier and rapidly developing regions: the middle socio-demographic index group showed the fastest-rising incidence, with an estimated annual percentage change of 4.34%, while the Caribbean rose faster still at 5.71% and Qatar steepest of all at 10.25% [s1]. In absolute numbers the United States recorded the most cases, at 11,845, and Monaco the highest incidence rate, at 32.89 per 100,000 [s1]. Why incidence keeps rising is not settled; the analysis projects it to keep climbing to 2035 even as mortality and disability rates may fall further [s1].

Why the numbers are reassuring

The figure that matters most is the distance between cases and deaths. Roughly 91,500 diagnoses and roughly 11,400 deaths in the same year describe a cancer that most men survive [s1]. Treatment is built around orchiectomy — surgical removal of the affected testicle — followed, depending on the tumour type and stage, by surveillance, chemotherapy or radiotherapy [s2]. A contemporary review describes the field's central preoccupation as avoiding overtreatment: because survival is so high, the modern emphasis is on active surveillance for low-risk tumours and less morbid surgery, rather than on treating harder [s3].

That same review notes that rising use of high-resolution scrotal ultrasound is turning up more small testicular masses, most of which are benign — a reminder that finding more lumps is not the same as finding more cancer [s3]. Newer molecular markers such as microRNA-371a-3p now show more than 90% sensitivity for viable germ-cell tumours, better than the classical blood markers, though they cannot detect every tumour subtype [s3].

Why the guidelines say not to screen

It is precisely because testicular cancer is already so treatable that population screening struggles to help. The U.S. Preventive Services Task Force recommends against screening for testicular cancer in adolescent or adult men — a Grade D recommendation, meaning it judges the harms to equal or outweigh the benefits [s2]. Its reasoning is blunt: there is "inadequate evidence that screening asymptomatic patients by means of self-examination or clinician examination has greater yield or accuracy for detecting testicular cancer at more curable stages" [s2].

This is one of the more counterintuitive positions in cancer prevention, because the routine "check yourself monthly" advice is so widespread. The Task Force is not saying self-exam is harmful in itself; it is saying there is no evidence it moves outcomes, in a cancer where outcomes are already excellent and where most cases present because a man notices a change himself and seeks care [s2]. That is different from ignoring symptoms — a new lump, swelling, or heaviness in a testicle warrants prompt evaluation, precisely because catching and treating the disease when it does appear is what keeps survival high [s2].

The honest summary is a two-part one that the popular framing usually collapses. Testicular cancer is becoming more common and deserves attention when symptoms appear [s1]. But the specific ritual of asymptomatic screening is not supported by evidence, and a young man who has never been told to perform monthly self-exams is not, on the current data, at any measurable disadvantage [s2].

For prostate cancer, where the screening question is genuinely contested, see our review of what the prostate-screening trials actually show and of active surveillance outcomes. Testicular tumours are also a recognised, if rare, cause of gynecomastia.

This article is informational and is not medical advice. A new lump, swelling, or change in a testicle should be evaluated by a clinician.